# Vincent A. Miller

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/vincent-a-miller/

## Facts

| Field | Value |
| --- | --- |
| Citations | 91,125 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 127 |
| i10-index | 393 |
| Last Known Institution | Universidad San Carlos |
| OpenAlex ID | https://openalex.org/A5111578811 |
| ORCID iD | https://orcid.org/0000-0003-1667-3771 |
| Works | 1,166 |

## Researcher papers

Showing 12 of 26.

- [International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma](https://scholariq.org/papers/international-association-for-the-study-of-lung-cancer-american-thoracic-society/)
- [EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib](https://scholariq.org/papers/egf-receptor-gene-mutations-are-common-in-lung-cancers-from-never-smokers-and/)
- [Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden](https://scholariq.org/papers/analysis-of-100-000-human-cancer-genomes-reveals-the-landscape-of-tumor/)
- [Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain](https://scholariq.org/papers/acquired-resistance-of-lung-adenocarcinomas-to-gefitinib-or-erlotinib-is/)
- [Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with <i>EGFR</i> -Mutant Lung Cancers](https://scholariq.org/papers/analysis-of-tumor-specimens-at-the-time-of-acquired-resistance-to-egfr-tki/)
- [Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers](https://scholariq.org/papers/tumor-mutational-burden-as-an-independent-predictor-of-response-to-immunotherapy/)
- [Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing](https://scholariq.org/papers/development-and-validation-of-a-clinical-cancer-genomic-profiling-test-based-on/)
- [Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing](https://scholariq.org/papers/mapping-the-hallmarks-of-lung-adenocarcinoma-with-massively-parallel-sequencing/)
- [<i>STK11/LKB1</i> Mutations and PD-1 Inhibitor Resistance in <i>KRAS</i>-Mutant Lung Adenocarcinoma](https://scholariq.org/papers/i-stk11-lkb1-i-mutations-and-pd-1-inhibitor-resistance-in-i-kras-i-mutant-lung/)
- [<i>MET</i> amplification occurs with or without <i>T790M</i> mutations in <i>EGFR</i> mutant lung tumors with acquired resistance to gefitinib or erlotinib](https://scholariq.org/papers/i-met-i-amplification-occurs-with-or-without-i-t790m-i-mutations-in-i-egfr-i/)
- [KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib](https://scholariq.org/papers/kras-mutations-and-primary-resistance-of-lung-adenocarcinomas-to-gefitinib-or/)
- [TRIBUTE: A Phase III Trial of Erlotinib Hydrochloride (OSI-774) Combined With Carboplatin and Paclitaxel Chemotherapy in Advanced Non–Small-Cell Lung Cancer](https://scholariq.org/papers/tribute-a-phase-iii-trial-of-erlotinib-hydrochloride-osi-774-combined-with/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)

## Researcher university

- [Universidad San Carlos](https://scholariq.org/institutions/universidad-san-carlos/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.